Berry Drug Of Dardanelle Durable Medical Equipment & Medical Supplies Location: 417 Union St, Dardanelle, Arkansas 72834 Phone: (479) 229-4811 |
Wal Mart Pharmacy 100296 Durable Medical Equipment & Medical Supplies Location: 1172 Old Highway 7 S, Dardanelle, Arkansas 72834 Phone: (479) 229-2157 |
News Archive
Despite significant medical advances, there continue to be significant gaps in the health care of the growing number of patients with valvular heart disease. In the USA, the total number of people aged 65 years or older with valvular heart disease will grow to approximately 5.2 million by year 2020, and 6.8 million individuals by the year 2030. The Minneapolis Heart Institute Foundation- has created a scientific program, "Valve Summit 2014: The Science and Delivery of Optimal, Multi-Disciplinary Care," to address the ongoing, complex evolution in the clinical management of patients with valvular heart disease. The conference will be held on April 25th and 26th at the Radisson Blu in downtown Minneapolis.
Investigators from the International Center for Biomedicine and the University of Chile, in collaboration with the Center for Bioinformatics of the Universidad de Talca, have discovered that two drugs, the benzimidazole derivatives lanzoprazole and astemizole, may be suitable for use as PET (positron emission tomography) radiotracers and enable imaging for the early detection of Alzheimer's Disease. The study is published in the current issue of the Journal of Alzheimer's Disease.
If you think sleep problems and bladder problems are a fact of life in old age, you may be right. A new report appearing in the November 2014 issue of The FASEB Journal, shows that our sleep-wake cycles are genetically connected to our bladder, and disruptions to one may cause problems with the other.
PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc. announced today the execution of an agreement under which PharmaEngine grants back to Merrimack the rights to develop, manufacture, and commercialize PEP02 in Asia and Europe, with the exception of Taiwan.
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
› Verified 7 days ago